• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket

    12/21/22 6:02:13 AM ET
    $ADCT
    $AEI
    $ATNF
    $BRDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate
    Finance
    Get the next $ADCT alert in real time by email

    Gainers

    • ADC Therapeutics SA (NASDAQ:ADCT) shares rose 36.8% to $4.35 in pre-market trading. ADC Therapeutics and Sobi announced European Commission approval of ZYNLONTA for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
    • Energy Focus, Inc. (NASDAQ:EFOI) rose 22.1% to $0.3899 in pre-market trading after declining 11% on Tuesday. Energy Focus, last month, posted a Q3 loss of $0.29 per share.
    • Caravelle International Group (NASDAQ:CACO) shares rose 21.8% to $2.57 in pre-market trading after dropping 57% on Tuesday.
    • 180 Life Sciences Corp. (NASDAQ:ATNF) rose 18.8% to $2.65 in pre-market trading. 180 Life Sciences Corp shares dropped 15% on Tuesday after the company announced a $6 million registered direct offering.
    • Grove Collaborative Holdings, Inc. (NYSE:GROV) rose 17.3% to $0.2398 in pre-market trading. Grove announced receipt of continued listing standards notice from NYSE.
    • TransCode Therapeutics, Inc. (NASDAQ:RNAZ) rose 17.2% to $0.3880 in pre-market trading after dropping 27% on Tuesday.
    • NIKE, Inc. (NYSE:NKE) rose 13.1% to $116.70 in pre-market trading after the company reported better-than-expected results for its second quarter on Tuesday.
    • Digital Ally, Inc. (NASDAQ:DGLY) shares rose 12% to $0.3096 in pre-market trading after gaining 13% on Tuesday.
    • Smart for Life, Inc. (NASDAQ:SMFL) rose 11.5% to $0.2599 in pre-market trading after jumping 16% on Tuesday.
    • Bird Global, Inc. (NYSE:BRDS) rose 9.7% to $0.1755 in pre-market trading after dropping 10% on Tuesday. Bird Global announced proposed merger with profitable partner Bird Canada.
    • Lottery.com Inc. (NASDAQ:LTRY) rose 8% to $0.2425 in pre-market trading after dropping 7% on Tuesday.
    • Invitae Corporation (NYSE:NVTA) rose 7.1% to $1.95 in pre-market trading after declining 7% on Tuesday.
    • FedEx Corporation (NYSE:FDX) rose 4.5% to $171.69 in pre-market trading. FedEx posted upbeat earnings for its second quarter, while sales missed expectations. The company also said it sees FY23 earnings of $13.00 to $14.00 per share, versus analysts’ estimates of $14.08 per share.


    Don’t forget to check out our premarket coverage here .


    Losers

    • Celyad Oncology SA (NASDAQ:CYAD) fell 46.2% to $0.56 in pre-market trading after the company issued an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property.
    • Core Scientific, Inc. (NASDAQ:CORZ) shares fell 31.5% to $0.1427 in pre-market trading. Core Scientific is filing for Chapter 11 bankruptcy protection on early Wednesday morning, CNBC reported, citing sources.
    • E-Home Household Service Holdings Limited (NASDAQ:EJH) shares fell 15.5% to $0.45 in pre-market trading. E-Home Household Services entered into definitive equity transfer agreement for acquisition of 20% equity interests in Zhongrun Pharmaceutical.
    • Spruce Biosciences, Inc. (NASDAQ:SPRB) fell 14.3% to $0.90 in pre-market trading after gaining 4% on Tuesday.
    • Alset Inc. (NASDAQ:AEI) fell 14.1% to $0.16 in pre-market trading after jumping 23% on Tuesday.
    • Erayak Power Solution Group Inc. (NASDAQ:RAYA) fell 13% to $2.35 in pre-market trading after jumping over 47% on Tuesday.
    • NantHealth, Inc. (NASDAQ:NH) fell 9.5% to $3.32 in pre-market trading after dropping over 12% on Tuesday. NantHealth recently announced a 1-for-15 reverse stock split.
    • Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) shares fell 9.1% to $0.3450 in pre-market trading. Creative Medical Technology, last month, announced FDA clearance of investigational new drug application for AlloStem.
    • Cosmos Health Inc. (NASDAQ:COSM) fell 9% to $7.97 in pre-market trading after gaining 15% on Tuesday. Cosmos Health recently announced pricing of a $32.5 million registered direct offering and concurrent private placement priced at-the-market.
    • Markforged Holding Corporation (NASDAQ:MKFG) fell 8.5% to $0.7908 in pre-market trading after gaining 7% on Tuesday.
    • IMV Inc. (NASDAQ:IMV) fell 8.2% to $2.57 in pre-market trading. IMV announced closing of $9 million registered direct offering priced at-the-market under Nasdaq rules.
    • Terns Pharmaceuticals, Inc. (NASDAQ:TERN) fell 8.1% to $7.77 in pre-market trading after the company reported pricing of $75 million public offering.
    • Exicure, Inc. (NASDAQ:XCUR) shares fell 7.7% to $0.72 in pre-market trading. Exicure Inc recently announced the termination of its collaboration agreements with AbbVie Inc and Ipsen BioPharm Limited.

    Also read this: Why Fear Level Among US Investors Is Increasing

    Get the next $ADCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADCT
    $AEI
    $ATNF
    $BRDS

    CompanyDatePrice TargetRatingAnalyst
    FedEx Corporation
    $FDX
    2/25/2026$335.00Hold → Reduce
    HSBC Securities
    FedEx Corporation
    $FDX
    2/13/2026$313.00 → $383.00Buy
    TD Cowen
    Terns Pharmaceuticals Inc.
    $TERN
    2/9/2026$58.00Outperform
    Leerink Partners
    FedEx Corporation
    $FDX
    2/3/2026$380.00Equal Weight → Overweight
    Wells Fargo
    FedEx Corporation
    $FDX
    2/3/2026$427.00Mkt Perform → Outperform
    Bernstein
    FedEx Corporation
    $FDX
    1/21/2026$271.00Buy → Neutral
    Rothschild & Co Redburn
    FedEx Corporation
    $FDX
    1/13/2026$280.00Outperform → Neutral
    BNP Paribas Exane
    FedEx Corporation
    $FDX
    1/9/2026$365.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ADCT
    $AEI
    $ATNF
    $BRDS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.

    SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

    2/24/26 4:47:27 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    2/23/26 8:10:39 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics SA filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - ADC Therapeutics SA (0001771910) (Filer)

    2/23/26 7:15:32 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $AEI
    $ATNF
    $BRDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/CEO Subramaniam Rajesh exercised 13,225 shares at a strike of $162.82 and covered exercise/tax liability with 8,330 shares, increasing direct ownership by 6% to 85,771 units (SEC Form 4)

    4 - FEDEX CORP (0001048911) (Issuer)

    2/20/26 4:34:12 PM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    President & CEO Yurcisin Jeffrey Michael converted options into 68,291 shares and covered exercise/tax liability with 20,660 shares, increasing direct ownership by 9% to 562,026 units (SEC Form 4)

    4 - Grove Collaborative Holdings, Inc. (0001841761) (Issuer)

    2/19/26 2:31:40 PM ET
    $GROV
    Catalog/Specialty Distribution
    Consumer Discretionary

    CFO Siragusa Thomas converted options into 23,018 shares and covered exercise/tax liability with 9,458 shares, increasing direct ownership by 22% to 74,003 units (SEC Form 4)

    4 - Grove Collaborative Holdings, Inc. (0001841761) (Issuer)

    2/19/26 2:30:00 PM ET
    $GROV
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ADCT
    $AEI
    $ATNF
    $BRDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    FedEx downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded FedEx from Hold to Reduce and set a new price target of $335.00

    2/25/26 11:18:50 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    TD Cowen reiterated coverage on FedEx with a new price target

    TD Cowen reiterated coverage of FedEx with a rating of Buy and set a new price target of $383.00 from $313.00 previously

    2/13/26 8:02:23 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    Leerink Partners initiated coverage on Terns Pharmaceuticals with a new price target

    Leerink Partners initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $58.00

    2/9/26 6:54:14 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $AEI
    $ATNF
    $BRDS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:04:01 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:03:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:

    4/23/21 1:46:03 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $AEI
    $ATNF
    $BRDS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ADCT
    $AEI
    $ATNF
    $BRDS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UPDATE: NIKE, Inc. Announces Third Quarter Fiscal 2026 Earnings and Conference Call

    To accommodate for several holidays, NIKE, Inc. (NYSE:NKE) now plans to release its third quarter fiscal 2026 financial results on Tuesday, March 31, 2026, at approximately 1:15 p.m. PT, following the close of regular stock market trading hours. Following the news release, NIKE, Inc. management will host a conference call beginning at 2:00 p.m. PT to review results. The conference call will be broadcast live over the Internet and can be accessed at https://investors.nike.com/. For those unable to listen to the live broadcast, an archived version will be available at the same location through 9:00 p.m. PT, April 23, 2026. About NIKE, Inc. NIKE, Inc., headquartered in Beaverton, Oregon,

    2/27/26 3:58:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    NIKE, Inc. Announces Third Quarter Fiscal 2026 Earnings and Conference Call

    NIKE, Inc. (NYSE:NKE) plans to release its third quarter fiscal 2026 financial results on Thursday, April 2, 2026, at approximately 1:15 p.m. PT, following the close of regular stock market trading hours. Following the news release, NIKE, Inc. management will host a conference call beginning at 2:00 p.m. PT to review results. The conference call will be broadcast live over the Internet and can be accessed at https://investors.nike.com/. For those unable to listen to the live broadcast, an archived version will be available at the same location through 9:00 p.m. PT, April 23, 2026. About NIKE, Inc. NIKE, Inc., headquartered in Beaverton, Oregon, is the world's leading designer, markete

    2/26/26 5:00:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

    FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March. TD Cowen's 46th Annual Health Care ConferenceFormat: Fireside ChatDate and Time: Monday, March 2, 2026 at 3:50 p.m. ET Location: Boston, MA Leerink Global Healthcare Conference Format: Fireside ChatDate and Time: Monday, March 9, 2026 at 1:40 p.m. ET Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Format: 1x1 MeetingsDate: Tuesday, March 10, 2026Location: Miami, FL The Citizens Li

    2/25/26 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $AEI
    $ATNF
    $BRDS
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    FedEx Appoints Scott Ray as Chief Operating Officer for U.S. and Canada Surface Operations

    FedEx Corp. (NYSE:FDX) today announced the appointment of Scott Ray as chief operating officer for U.S. and Canada Surface Operations, effective June 1. He will begin transitioning into the role as COO-elect on Feb. 1. Reporting to FedEx President and CEO Raj Subramaniam, Ray will be the newest member of the FedEx Executive Committee, succeeding John Smith, who will transition to CEO of FedEx Freight as of June 1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126094399/en/FedEx appoints Scott Ray as chief operating officer of Surface Operations in U.S. and Canada Ray will be responsible for leading all aspects of Surface Ope

    1/27/26 8:31:00 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    Cinch Home Services Welcomes Digital Transformation Leader Kristine Miller to its Board of Advisors

    BOCA RATON, Fla., Jan. 22, 2026 /PRNewswire/ -- Cinch Home Services today announced the appointment of Kristine (Kris) Miller to its Board of Advisors. Miller is a highly regarded digital, strategy, and transformation leader with more than two decades of experience helping organizations modernize, scale, and deliver customer-centered growth across complex, consumer-facing businesses. As a member of the Board, she will help guide Cinch Home Services' strategic direction as the company continues to expand its mission of simplifying home ownership through innovative and reliable home protection solutions. 

    1/22/26 1:00:00 PM ET
    $GROV
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ADCT
    $AEI
    $ATNF
    $BRDS
    Financials

    Live finance-specific insights

    View All

    UPDATE: NIKE, Inc. Announces Third Quarter Fiscal 2026 Earnings and Conference Call

    To accommodate for several holidays, NIKE, Inc. (NYSE:NKE) now plans to release its third quarter fiscal 2026 financial results on Tuesday, March 31, 2026, at approximately 1:15 p.m. PT, following the close of regular stock market trading hours. Following the news release, NIKE, Inc. management will host a conference call beginning at 2:00 p.m. PT to review results. The conference call will be broadcast live over the Internet and can be accessed at https://investors.nike.com/. For those unable to listen to the live broadcast, an archived version will be available at the same location through 9:00 p.m. PT, April 23, 2026. About NIKE, Inc. NIKE, Inc., headquartered in Beaverton, Oregon,

    2/27/26 3:58:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    NIKE, Inc. Announces Third Quarter Fiscal 2026 Earnings and Conference Call

    NIKE, Inc. (NYSE:NKE) plans to release its third quarter fiscal 2026 financial results on Thursday, April 2, 2026, at approximately 1:15 p.m. PT, following the close of regular stock market trading hours. Following the news release, NIKE, Inc. management will host a conference call beginning at 2:00 p.m. PT to review results. The conference call will be broadcast live over the Internet and can be accessed at https://investors.nike.com/. For those unable to listen to the live broadcast, an archived version will be available at the same location through 9:00 p.m. PT, April 23, 2026. About NIKE, Inc. NIKE, Inc., headquartered in Beaverton, Oregon, is the world's leading designer, markete

    2/26/26 5:00:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Core Scientific, Inc. Schedules Fourth Quarter Fiscal Year 2025 Earnings Release, Conference Call and Webcast

    Core Scientific, Inc. (NASDAQ:CORZ) ("Core Scientific" or the "Company"), a leader in digital infrastructure for high-density colocation, today announced it will release its fourth quarter and fiscal year 2025 financial results after the financial markets close on Monday, March 2, 2026. Management will host a conference call and live audio webcast to discuss the results at 3:30 p.m. Central Time. Hosting the call and webcast to review results for the fourth quarter and fiscal year 2025 will be Adam Sullivan, Chief Executive Officer, Matt Brown, Chief Operating Officer, Jim Nygaard, Chief Financial Officer, and Jon Charbonneau, Vice President, Investor Relations. Conference Call and Webc

    2/23/26 7:00:00 AM ET
    $CORZ
    Finance: Consumer Services
    Finance

    $ADCT
    $AEI
    $ATNF
    $BRDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/14/24 9:00:57 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care